Clinical Trial Update: Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated TP10, a complement inhibitor, for safety and efficacy in adult women undergoing cardiopulmonary bypass surgery.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aortic Valve Insufficiency
• Coronary Arteriosclerosis
• Mitral Valve Insufficiency
• Myocardial Ischemia

Drugs mentioned

• TP10

Snippet

Sponsor: Avant Immunotherapeutics | Conditions: Myocardial Ischemia, Coronary Arteriosclerosis | Phase 2 | Status: COMPLETED